阅读说明：本技术 具有减少的病毒和微生物污染的酶组合物 (Enzyme compositions with reduced viral and microbial contamination ) 是由 M.巴布科克 C.伯内尔 V.卡尔索德 J.布雷滕巴赫 F.塞斯尼 F-R.吕费尔 G. 于 2018-09-27 设计创作，主要内容包括：本发明涉及从电子束照射的动物组织例如猪胰腺中获得的酶制剂。本发明还涉及用于制备此类酶制剂的方法,包含此类酶制剂的药物组合物,以及关于使用此类药物组合物和酶制剂的方法。(The present invention relates to enzyme preparations obtained from electron beam irradiated animal tissue, such as porcine pancreas. The invention also relates to processes for preparing such enzyme preparations, pharmaceutical compositions comprising such enzyme preparations, and to methods for using such pharmaceutical compositions and enzyme preparations.)

1. An enzyme preparation produced by a method comprising the steps of:

(a) subjecting intact mammalian pancreatic tissue to electron beam radiation to produce irradiated pancreatic tissue, wherein the electron beam radiation is sufficient to produce at least three logs of the viral load of the model virus as compared to a control sample₁₀Reduction; and

(b) pancreatic juice is isolated from the irradiated pancreatic tissue.

2. The enzyme preparation of claim 1, wherein the electron beam radiation is sufficient to produce at least four logs of the viral load of the model virus as compared to a control sample₁₀And (4) reducing.

3. The enzyme preparation of claim 1, wherein the model virus is Porcine Parvovirus (PPV).

4. The enzyme preparation of claim 1, wherein the intact mammalian pancreatic tissue is a lamellar tissue, a whole gland, or a portion of a whole gland.

5. The enzyme preparation of claim 1, wherein step (b) comprises initiating hydrolysis or autolysis of the irradiated pancreatic tissue, or activating a zymogen from the irradiated pancreatic tissue.

6. The enzyme preparation according to claim 1, wherein the biological activity of the enzyme preparation obtained in step (b) corresponds to at least 80% of the biological activity of a control enzyme preparation.

7. The enzyme preparation of claim 6, wherein the biological activity is lipase activity.

8. The enzyme preparation of claim 1, wherein the electron beam radiation has a dose of about 5 to about 50 kGy.

9. An enzyme preparation comprising one or more enzymes isolated from electron beam irradiated pancreatic tissue.

10. The enzyme preparation of claim 9, wherein the electron beam irradiated pancreatic tissue is a sheet of pancreatic tissue, a whole pancreatic gland, or a portion of a whole pancreatic gland.

11. The enzyme preparation of claim 9, wherein the one or more enzymes comprise pancreatin.

12. The enzyme preparation according to claim 9, wherein the biological activity of the enzyme preparation corresponds to at least 80% of the biological activity of a control enzyme preparation.

13. The enzyme preparation of claim 12, wherein the biological activity is lipase activity.

14. A method for producing a pancreatin product, comprising the steps of:

(a) subjecting intact mammalian pancreatic tissue to electron beam radiation to produce irradiated pancreatic tissue; and

(b) pancreatic juice is isolated from the irradiated pancreatic tissue.

15. The method of claim 14, wherein the biological activity of the pancreatin product obtained in step (b) corresponds to at least 80% of the biological activity of a control enzyme preparation.

16. The method of claim 14, wherein the electron beam radiation is sufficient to produce at least three logs of the viral load of the model virus as compared to the control sample₁₀Wherein the model virus is Porcine Parvovirus (PPV).

17. The method of claim 14, wherein the electron beam radiation has a dose of about 5 to about 50 kGy.

18. The method of claim 15, wherein the biological activity is lipase activity.

19. A pharmaceutical composition comprising the enzyme preparation of claim 1.

20. A method of treating exocrine pancreatic insufficiency, comprising:

administering to a subject in need thereof a dose of the enzyme preparation of claim 1.

21. The method of claim 20, wherein said pancreatic exocrine insufficiency is due to cystic fibrosis or chronic pancreatitis.

Technical Field

The present invention relates to enzyme preparations derived from animal tissue, pharmaceutical compositions comprising such enzyme preparations, and methods for reducing the risk of viral and microbial contamination in such preparations and compositions. Exemplary enzyme compositions include pancreatic extracts suitable for therapeutic use in mammals and humans, for example for the treatment and/or prevention of dyspepsia, and in particular dyspepsia based on chronic exocrine pancreatic insufficiency.

Background

Products derived from animal tissue may exhibit viral and/or microbial contamination. During the manufacturing process, certain biological contaminants such as bacteria or protozoa may be inactivated. However, other biological contaminants, such as non-enveloped viruses and certain spore-forming bacteria (e.g., Bacillus cereus: (B.))Bacillus cereus) Resistant to established methods for reducing or inactivating contaminants. A particular challenge is to inactivate or remove viruses and spore-forming bacteria from enzyme compositions derived from animal tissue without destroying or altering the activity of the enzyme in the process.

Established methods for viral inactivation include, for example, pasteurization, dry heat, steaming, solvent/detergent treatment, and low pH. The choice of the method to be used for virus inactivation depends on the nature and contamination of the product, the purification method used (if present), and the nature of the viral contaminants. For example, solvent or detergent treatment can disrupt the lipid membrane of enveloped viruses and has therefore been used to inactivate enveloped viruses. However, many non-enveloped viruses are generally not inactivated by solvent or detergent treatment. Similarly, many spore-forming bacteria are resistant to both heat and organic solvents.

Heating, particularly dry heat, is another established method for virus inactivation. Although dry heat treatment can even inactivate highly resistant viruses (e.g., non-enveloped viruses), the treatment requires extended periods of time (hours) as well as moisture monitoring. Furthermore, heat treatment can impair the desired biological activity of the product, particularly when the product is an enzyme composition.

Pancreatic enzyme products have long been used to treat pancreatic exocrine insufficiency, conditions associated with Cystic Fibrosis (CF), chronic pancreatitis, pancreatic or common bile duct obstruction (e.g., from neoplastic disease), surgery such as pancreatectomy or gastrointestinal bypass surgery, and other diseases and disorders. The pancreas secretes digestive enzymes (including lipases, proteases and amylases) into the proximal duodenum lumen, where they promote the hydrolysis of macronutrients. Amylases and proteases are secreted by organs other than the pancreas, and these contribute to the digestion of carbohydrates and proteins. However, there are relatively few lipases from sources other than the pancreas that are involved in lipid digestion. Thus, patients with untreated exocrine pancreatic insufficiency often have difficulty digesting fat and may suffer from dyspepsia or malnutrition or both, with deficiencies in essential fatty acids and fat-soluble vitamins, weight loss, abdominal cramps, flatulence, abdominal distension and greasiness, foul odors, watery stools (lipolysis). For CF patients, inappropriate treatment can have serious consequences, as good nutritional status has been directly associated with good lung function.

Pancreatin therapy treats and/or avoids malabsorption and promotes growth and development in patients with exocrine pancreatic insufficiency. In CF patients, mucus blocks the pancreatic ducts in the pancreas as in the lungs. Digestive enzymes of the pancreas are not secreted into the intestine, and thus digestion of starch, fat and protein is impaired. Lack of digestion leads to, inter alia, steatorrhea, abdominal pain and weight loss.

Dyspepsia in mammals and humans is usually based on a deficiency of digestive enzymes, in particular on a deficiency of endogenous lipases, but also on a deficiency of proteases and/or amylases. If pancreatic insufficiency is pathological, this may be congenital or acquired. Acquired chronic pancreatic insufficiency may be attributed, for example, to alcoholism. Congenital pancreatic insufficiency may for example be ascribed to the congenital disease cystic fibrosis. The consequences of digestive enzyme deficiency can be severe symptoms of undernutrition and malnutrition, which may be accompanied by increased susceptibility to secondary disease.

Substitution with exogenous digestive enzymes or mixtures of digestive enzymes (i.e., pancreatin) has proven to be an effective treatment for endogenous digestive enzyme deficiencies. Most frequently, pharmaceutical preparations containing porcine pancreatin are used in pancreatin therapy (also referred to as "enzyme replacement therapy"). For such pharmaceutical preparations, the active ingredient evaluated in clinical trials is lipase, and the dose for the commercial product is given in lipase units. However, such digestive enzyme mixtures obtained from porcine pancreas contain lipases, amylases and proteases, and can be effectively used for pancreatin therapy in humans due to the great similarity of the enzymes and accompanying substances contained therein to the contents of human pancreatic juice. Pancreatin is usually administered orally in the form of a solid preparation.

The pancreatic glands may be obtained from raised and slaughtered animals for food such as pigs. Government regulations often require that pancreatic glands be obtained from a single species slaughterhouse (i.e., no slaughter and processing of other species at the facility) and thereby limit the availability of raw materials. Widespread contamination of facilities by pathogens can lead to production down-time and supply shortages. Current testing procedures can identify contaminated batches, and the elimination of such batches places a further burden on the otherwise already limited supply of raw materials.

Methods for obtaining pancreatin from mammalian pancreatic glands are available. For example, in US 4,623,624 a method is described by which pancreatin is obtained via autolysis of a tissue slurry containing aqueous isopropanol.

It is recognized that pathogens, particularly viruses and spore-forming bacteria, are present in porcine pancreas used for the production of pancreatin. In fact, most herds have been infected with Porcine Parvovirus (PPV), which is highly resistant to inactivation. PPV has been detected as a pathogen in pancreatic juice. Although PPV is not considered pathogenic to humans, it is desirable to obtain pancreatin with reduced PPV load. In addition, PPV is a common model virus because it is difficult to inactivate by standard methods (e.g., chemical or thermal processing). Similarly, contamination of pancreatic juice bulk drugs with bacillus cereus and/or bacillus cereus enterotoxin has been reported.

US 2010/0119654 relates to irradiation of an alcoholic or aqueous biological extract containing solids in the form of a suspension the radiation employed in US 2010/0119654 is Ultraviolet (UV) radiation, x-ray radiation, β radiation or gamma radiation dissolved in 40% isopropanolUV irradiation of the pancreatin intermediate product of (a) yields up to 4 log of M2 phage₁₀And (4) reducing. Gamma irradiation of pancreatin (API) produced approximately a 40% reduction in lipase activity at 27 kGy and a 13% reduction in lipase activity at 5 kGy. The bacteria content is reduced by more than 2.5 log₁₀Viral inactivation was not reported, however, when pancreatin (API) was treated with β irradiation,>85% enzyme activity is reported to be maintained, but the "bacterial count" is only reduced by about 1.5 log₁₀。

WO 2003/020324 relates to the sterilization of digestive enzymes, such as trypsin, α -galactosidase and iduronic acid 2-sulfatase, by irradiation, lyophilized or liquid enzymes (trypsin, glycosidase or sulfatase) alone or in the presence of a stabilizer⁶⁰The Co source completes the gamma irradiation. Viral inactivation was not reported.

WO 2007/014896 relates to the reduction of the concentration of one or more biological contaminants, in particular viral contaminants, of pancreatin by heating the pancreatin.

In US 2009/0233344, heat treatment of pancreatin at 80 ℃ for 32 hours provided about 2.5 log of PPV virus titer₁₀Reduction, and 20% loss in lipase activity. Heat treatment of pancreatin at 100 ℃ for 8 hours provided greater than 3log of PPV virus titer₁₀Reduced, but lost nearly 50% of lipase activity.

Thus, process steps that can be effectively directed against difficult to inactivate viruses such as PPV have a high potential for altering the properties of pancreatic juice product (by degrading or reducing pancreatic enzymes, particularly lipases) to unacceptable levels. Such changes in potency may reduce or alter the efficacy profile of the final product. Therefore, it is desirable to maintain enzymatic activity, particularly lipase activity, during the manufacturing process.

Since previously tested viral clearance processes that demonstrate some effectiveness against difficult to inactivate viruses (e.g., PPV) each result in significant loss of enzymatic activity (including lipase activity), the industry suspects whether strong levels of viral inactivation/clearance can be achieved without compromising product quality. In particular, the industry suspects whether suitable powerful orthogonal viral clearance steps can be developed without adversely affecting the chemical, physical or pharmaceutical properties of pancreatin. See, for example, the letters written by Scientific Protein Laboratories to the FDA on 6.2004-22.6.2004 in case No. 2003D-0206.

Summary of The Invention

The present invention relates to enzyme preparations isolated from animal tissue sources. The isolated enzyme preparation includes one or more enzymes, has reduced viral and/or microbial contamination relative to the source animal tissue, and maintains at least one biological activity of the source animal tissue. In certain embodiments, the enzyme preparation is produced by subjecting source animal tissue to radiation, preferably electron beam radiation, and subsequently isolating the one or more enzymes from the irradiated tissue. In certain embodiments, the source animal tissue is an intact tissue. In certain embodiments, the irradiated tissue exhibits at least three logs of viral and/or microbial contamination as compared to non-irradiated source animal tissue₁₀Preferably at least four logs₁₀And (4) reducing. In certain embodiments, the irradiated tissue exhibits at least three logs of viral load as compared to the source animal tissue₁₀Preferably at least four logs₁₀And (4) reducing. In certain embodiments, additional orthogonal viral reduction steps are employed (e.g., during the step of isolating one or more enzymes from the irradiated tissue). In certain embodiments, the enzyme preparation isolated from the irradiated tissue has a biological activity corresponding to at least 50%, preferably at least 90% of the biological activity of a control enzyme preparation, e.g., an enzyme preparation isolated from non-irradiated source animal tissue. In certain embodiments, the biological activity is lipase activity. In certain embodiments, the irradiated tissue exhibits at least three logs of viral and/or microbial contamination as compared to non-irradiated source animal tissue₁₀Preferably at least four logs₁₀Reduced and the enzyme preparation isolated from the irradiated tissue has a biological activity corresponding to at least 50%, preferably at least 90% of the biological activity of a control enzyme preparation, e.g. an enzyme preparation isolated from non-irradiated source animal tissue.

Another aspect of the inventionThe present invention relates to a process for producing an enzyme preparation derived from animal tissue, wherein the enzyme preparation has reduced viral and/or microbial contamination relative to the source animal tissue. The method comprises at least three logs of viral and/or microbial contaminants sufficient to produce compared to the source animal tissue₁₀Preferably at least four logs₁₀Reduced processing. In certain embodiments, the treatment comprises subjecting intact source animal tissue to radiation, preferably electron beam radiation, to produce irradiated animal tissue. In certain embodiments, the electron beam radiation treatment is sufficient to reduce viral and/or microbial contamination of the source animal tissue while maintaining at least one biological activity of the source animal tissue. In certain embodiments, the biological activity is lipase activity. In certain embodiments, one or more enzymes and/or zymogens are extracted from the irradiated animal tissue. In certain embodiments, the one or more enzymes are isolated from the irradiated animal tissue. In certain embodiments, the method reduces the risk of infectious contamination of the animal-derived enzyme preparation or the pharmaceutical composition comprising the animal-derived enzyme preparation relative to an untreated control.

Another aspect of the invention relates to a pharmaceutical composition comprising an enzyme preparation as described herein. The pharmaceutical composition may be in an oral pharmaceutical dosage form. In certain embodiments, the pharmaceutical compositions are used to treat or prevent diseases that respond to pancreatic enzyme replacement therapy, such as exocrine pancreatic insufficiency. Thus, another aspect of the invention relates to a method for treating or preventing exocrine pancreatic insufficiency, comprising administering to a subject in need thereof a dose of an enzyme preparation or pharmaceutical composition described herein.

Another aspect of the invention relates to a kit comprising an enzyme preparation or a pharmaceutical composition as described herein.

These and other objects of the invention are described in the following paragraphs. These objects should not be construed to narrow the scope of the invention.

Detailed Description

This detailed description is merely intended to acquaint others skilled in the art with the invention, its principles, and its practical application so that others skilled in the art may adapt and apply the invention in its numerous forms, as may be best suited to the requirements of a particular use. This description and its specific examples are intended for purposes of illustration only. Therefore, the present invention is not limited to the embodiments described in the patent application, and various modifications can be made.

A. Definition of

As used in the specification and the appended claims, unless specified to the contrary, the following terms have the indicated meanings:

as used herein, the term "API" stands for "active pharmaceutical ingredient". As disclosed herein, a preferred API is pancreatin, in particular porcine pancreatin as generally used for therapeutic purposes, i.e. pancreatin according to the requirements of standard pharmacopoeias such as the european pharmacopoeia and/or USP, and is suitable for oral administration (e.g. in patients suffering from cystic fibrosis, chronic pancreatitis or patients having undergone surgery on the digestive tract) in the treatment or prevention of dyspepsia in mammals, in particular humans, and in particular dyspepsia due to chronic exocrine pancreatic insufficiency.

As used herein, the term "crude" refers to a non-purified preparation or mixture containing the enzyme and/or proenzyme and additional components derived from the source tissue. Crude preparations or mixtures include, but are not limited to, animal tissue itself.

The term "enzyme preparation" refers to any composition of matter containing one or more enzymes, whether in active or inactive form (i.e., proenzyme or zymogen). The term includes cell or tissue extracts, as well as crude preparations derived from animal tissue or other cellular material. An example of an enzyme preparation is pancreatin, pancrelipase, an extract derived from the pancreas of a mammal, preferably a pig.

The term "extract" when it relates to the presented enzyme preparation refers to one or more enzymes and/or zymogens that have been separated from at least one component of the tissue from which they are derived. The extracted component may be in the form of an active enzyme or a proenzyme (zymogen) which requires subsequent conversion to an active form.

The term "isolate" when it relates to an enzyme preparation presented, refers to one or more active enzymes that have been separated from at least one component of the tissue from which they are derived. Thus, in certain embodiments, an "isolated enzyme" or "isolated enzyme preparation" comprises one or more active enzymes that have been converted from the corresponding zymogen form by hydrolysis and/or autolysis. The hydrolysis and/or autolysis to convert the proenzyme into the active enzyme may take place before, during or after extraction.

As used herein, the terms "pancreatin", "pancreatin" and "pancrelipase" refer to an enzymatic mixture derived from the mammalian pancreas that contains digestive enzymes such as lipases, proteases and amylases as major components. In particular, the terms "pancreatin", "pancreatin" and "pancrelipase" may be used synonymously herein and refer to a pancreatic extract suitable for therapeutic use according to the standard pharmacopoeia, which contains several digestive enzymes, the properties of which are defined by the standard monographs as explained above. Due to standard manufacturing processes, "pancreatin" and "pancrelipase" are usually provided in powder form as "pancreatin meal", sometimes also referred to as "pancreas meal". Pancreatin, pancreatin and pancrelipase can also be and preferably are APIs. Pancreatin for pharmaceutical use is usually of bovine or porcine origin. Porcine pancreatic juice is preferred. Pancreatic lipase has been described in some references as an enzyme preparation with increased activity (lipase) relative to pancreatin.

As used herein, the term "pharmaceutical composition" means a composition comprising an enzyme preparation as described herein and optionally one or more pharmaceutically acceptable excipients.

The term "pharmaceutically acceptable" is used adjectively to mean that the modified noun is suitable for use as a drug product or portion of a drug product.

An "orthogonal" microorganism and/or virus reduction step refers to a differential method for reducing microorganisms and/or viruses that may be present in a sample. The microbial and/or viral reduction steps may be orthogonal provided that one or more additional microorganisms and/or viruses are present in the processThe method has few steps. In certain embodiments, an "orthogonal" microorganism and/or virus reduction step has a mechanism sufficiently distinct from all other microorganism and/or virus reduction steps used in the process such that the log achieved by the "orthogonal" step₁₀Log cumulative log of kill becoming equal to that achieved from all other microbial and/or viral reduction steps used to obtain the enzyme preparation₁₀The kill phase.

The terms "preventing", "preventing" and "prevention" refer to a method of preventing the onset of a condition, disorder or disease and/or its attendant symptoms, or preventing a subject from acquiring a condition, disorder or disease. As used herein, "preventing" and "prevention" also include delaying the onset of a condition, disorder or disease and/or its attendant symptoms, and reducing the risk of the subject acquiring the condition, disorder or disease.

The term "subject" includes humans and other primates, as well as domesticated and semi-domesticated animals, including, but not limited to, poultry, bees, cows, sheep, goats, pigs, horses, dogs, cats, rabbits, rats, mice, and the like. The term "poultry" encompasses all types of domesticated birds including, but not limited to, chickens, turkeys, ducks, geese, ratites, and game birds. In certain embodiments, the subject is a human.

The term "therapeutically effective amount" means a sufficient amount of an enzyme preparation or pharmaceutical composition to treat a condition, disorder or disease at a reasonable benefit/risk ratio applicable to any medical treatment. When used in medical therapy, a therapeutically effective amount of an enzyme preparation may be employed as an extract or in crude form. Alternatively, the enzyme composition may be administered as a pharmaceutical composition containing the enzyme composition of interest in combination with one or more pharmaceutically acceptable carriers.

The terms "treat", "treating" and "treatment" refer to a method of alleviating or eliminating a condition, disorder or disease and/or its attendant symptoms.

B. Enzyme preparation and preparation method

In one aspect, the invention includes an enzyme preparation comprising one or more enzymes and/or zymogens derived from animal tissue, preferably mammalian, tissue. In certain embodiments, the enzyme preparation comprises a mixture of digestive enzymes and/or zymogens. In certain embodiments, the enzyme preparation comprises a lipase. In certain embodiments, the enzyme preparation comprises an amylase. In certain embodiments, the enzyme preparation comprises a protease. In certain embodiments, the enzyme comprises pancreatin. In certain embodiments, the enzyme preparation comprises a proenzyme, such as a prolipase or trypsinogen. In certain embodiments, the enzyme preparation is in crude form. In certain embodiments, the enzyme preparation comprises one or more enzymes and/or zymogens that have been extracted from animal tissue. In certain embodiments, the enzyme preparation comprises one or more enzymes that have been isolated from animal tissue.

In certain aspects, an isolated enzyme preparation has the same or substantially the same biological activity as the tissue from which it was isolated, but is less infectious. In certain embodiments, the isolated enzyme preparation has the same or substantially the same biological activity as a control enzyme preparation. In certain embodiments, the infectivity of an isolated enzyme preparation is reduced by at least three logs relative to the infectivity of the tissue from which it was isolated₁₀Preferably at least four logs₁₀. In certain embodiments, the reduced infectivity is viral infectivity, in particular non-enveloped virus infectivity and/or enveloped virus infectivity. In certain embodiments, the biological activity of the isolated enzyme preparation is at least 50%, at least 60%, at least 70%, at least 80%, or preferably at least 90% of the biological activity of the control enzyme preparation. In certain embodiments, the biological activity is an enzymatic activity, such as a protease activity, an amylase activity, or preferably, a lipase activity.

In another aspect, the enzyme preparation is isolated from a pretreated tissue source and has the same or substantially the same biological activity, but is less infectious than a control preparation isolated from an untreated tissue source. In certain embodiments, the infectivity of the enzyme preparation is reduced by at least three logs relative to a control preparation₁₀Preferably at least four logs₁₀. In certain embodiments, the infectivity of the pretreated tissue source is reduced by at least three logs relative to an untreated tissue source₁₀Preferably at least four logs₁₀. In certain embodiments, the reduced infectivity is viral infectivity, particularly non-enveloped virus infectivity. In certain embodiments, the biological activity of the enzyme preparation is at least 50%, at least 60%, at least 70%, at least 80%, or preferably at least 90% of the biological activity of a control preparation isolated from an untreated tissue source. In certain embodiments, the biological activity is an enzymatic activity, such as a protease activity, an amylase activity, or preferably, a lipase activity.

In another aspect, the enzyme preparation is derived from electron beam irradiated tissue. In certain embodiments, the electron beam irradiated tissue is mammalian tissue, preferably porcine tissue. In certain embodiments, the enzyme derived from electron beam irradiated tissue comprises pancreatin. In certain embodiments, the enzyme preparation derived from electron beam irradiated tissue comprises a proenzyme, such as a prolipase or trypsinogen. In certain embodiments, the enzyme preparation derived from electron beam irradiated tissue is in a crude form. In certain embodiments, the enzyme preparation derived from electron beam irradiated tissue comprises one or more enzymes and/or zymogens that have been extracted from the irradiated tissue. In certain embodiments, the enzyme preparation derived from electron beam irradiated tissue comprises one or more enzymes that have been isolated from the irradiated tissue.

In another aspect, the enzyme preparation is isolated from electron beam irradiated tissue and has the same or substantially the same biological activity, but is less infectious than a control preparation isolated from a source of unirradiated tissue. In certain embodiments, the irradiated tissue is pancreatic tissue. In certain embodiments, the irradiated tissue is a flaked pancreatic tissue, an entire pancreatic gland, or a portion of an entire pancreatic gland. In certain embodiments, the non-irradiated tissue source is pancreatic tissue. In certain embodiments, the infectivity of the enzyme preparation is reduced by at least three logs relative to a control preparation₁₀Preferably at least four logs₁₀. In some instancesIn embodiments, the reduced infectivity is viral infectivity, particularly non-enveloped and/or enveloped virus infectivity. In certain embodiments, the decreased infectivity is PPV infectivity. In certain embodiments, the biological activity of the isolated enzyme preparation is at least 50%, at least 60%, at least 70%, at least 80%, or preferably at least 90% of the biological activity of the control preparation. In certain embodiments, the biological activity is an enzymatic activity, such as a protease activity, an amylase activity, or preferably, a lipase activity.

In another aspect, the enzyme preparation comprises an electron beam irradiated zymogen. In certain embodiments, the enzyme preparation is further processed, for example, by converting the irradiated zymogen into its active form (e.g., by autolysis and/or hydrolysis).

The enzyme preparation presented may be better understood in conjunction with the following methods which illustrate exemplary techniques by which enzyme preparations may be obtained.

In one aspect, the invention includes a method for preparing an enzyme composition comprising subjecting a proenzyme source to radiation, preferably electron beam radiation. In certain embodiments, the source of proenzymes is a population of cells. In certain embodiments, the population of cells is an intact tissue obtained from a mammalian gland or portion thereof. In certain embodiments, the cell population is obtained from the entire gland of a mammal. In certain embodiments, the cell population is a portion of a gland obtained from a mammal. In certain embodiments, the cell population is a frozen tissue mass. In certain embodiments, the cell population is a sheet or minced animal tissue.

In another aspect, the invention includes a method for preparing an enzyme preparation. The method comprises subjecting animal tissue to radiation, preferably electron beam radiation. In certain embodiments, the animal tissue is an intact tissue. In certain embodiments, the intact animal tissue is a frozen tissue mass. In certain embodiments, the intact animal tissue is a sheet or minced animal tissue.

In certain embodiments, the method begins with animal tissue, preferably intact animal tissue. In certain embodiments, the animal tissue is a mammalian pancreas, and preferably a porcine pancreas. In certain embodiments, the porcine pancreas is obtained from an approved slaughterhouse, preferably a single species slaughterhouse.

In certain embodiments, the intact animal tissue comprises intact pancreatic tissue. In certain embodiments, the intact pancreatic tissue comprises the entire pancreatic gland or a portion thereof, such as one or more lobes. In certain embodiments, the intact pancreatic tissue comprises a sheet of frozen tissue. In certain embodiments, intact pancreatic tissue comprises a frozen tissue mass, which may have been machined. In certain embodiments, intact pancreatic tissue includes pancreatic tissue that has been minimally manipulated or altered, or preferably not manipulated or altered, for example, by destroying active enzymes in the tissue and/or converting zymogens into their active form. For example, a tissue homogenate that undergoes significant chemical or enzymatic processing to convert a proenzyme into its active form is not "whole tissue" as that term is used herein. As another example, tissue that has been ground or minced is not "whole tissue" as that term is used herein under conditions that destroy active enzymes in the tissue and/or convert proenzymes into their active forms.

Chopping typically involves processing the source tissue in a mill to no more than 0.5 cm³Not more than 0.4 cm³Not more than 0.3 cm³Not more than 0.2 cm³Or not more than 0.1 cm³Small pieces of (a). Homogenization typically involves mixing the shredded material with water to form a slurry or suspension as is known in the art. The tissue may also be mixed with other solutions and/or stabilizers to allow or simplify mechanical processing, provided that mixing with other solutions and/or stabilizers does not destroy the active enzymes in the tissue and/or convert the proenzyme into its active form, for example by maintaining the temperature of the homogenate, suspension or slurry at 10 ℃ + 5 ℃, preferably below 10 ℃.

Thus, mechanical processing of tissue expressly encompasses adding or mixing water and/or lower alcohols (e.g., isopropanol) in sufficient amounts to allow or simplify mechanical processing such as chopping or homogenization, provided that the mixing/combining is not accompanied by autolysis or hydrolysis. Thus, the mechanical processing according to the method of the invention may be performed to maintain the tissue at 10 ℃ + 5 ℃, preferably below 10 ℃ (including freezing), during processing to minimize or stop autolysis or hydrolysis. Accordingly, for example, the tissue homogenate may be a mixture of both tissue and water, which has been maintained at 10 ℃ + 5 ℃, preferably below 10 ℃ during processing, in order to prevent the tissue from undergoing hydrolysis and/or autolysis.

In contrast, "in-process intermediates" (and similar terms) refer to tissues that have been subjected to one or more steps of chemical and/or enzymatic processing, including hydrolysis and autolysis, in addition to optional mechanical alteration from the source tissue. In particular, one or more steps of chemical and/or enzymatic processing alter the biomolecule population and/or the biomolecule profile, for example by disrupting active enzymes in the tissue and/or converting the proenzyme into its active form. Thus, intermediates in the process may also have altered ratios of proenzyme to active enzyme.

In certain embodiments, animal tissue, preferably frozen animal tissue, is comminuted. In certain embodiments, comminution may be achieved using a frozen block microtome, such as the hydraufrake shredder supplied by General Machinery Corporation (Sheboygan, WI), which is designed to slice frozen tissue in a formulation for further processing.

In certain embodiments, animal tissue is irradiated. In certain embodiments, animal tissue is exposed to a sterilizing beam of accelerated electrons, i.e., electron beam (E-beam or electron beam) radiation. In certain embodiments, intact animal tissue is exposed to electron beam irradiation. In certain embodiments, the entire pancreatic gland or an intact portion thereof is exposed to electron beam irradiation. In certain embodiments, the sheet of porcine pancreatic tissue is exposed to electron beam irradiation.

Electron beam radiation is a form of ionizing energy generally characterized by its low penetration and high dose rate. The beam (concentrated stream of highly charged electrons) is generated by electrical acceleration and conversion. The electrons are generated by a device called an accelerator, which is capable of producing a pulsed or continuous beam. Energy from the electrons is absorbed as the irradiated material passes under or in front of the electron beam. This energy absorption changes various chemical bonds and biological properties within the product/material. The energy absorbed is referred to as the "absorbed dose". It is this energy absorption (or "dose delivery") that destroys viruses and microorganisms, for example, by destroying their DNA or RNA strands.

Irradiation may be carried out in a conventional manner, for example by placing the tissue in a suitable container and exposing the tissue to an electron beam. In certain embodiments, the container containing the tissue is placed on a conveyor belt, which is then passed through an electron beam. In certain embodiments, the container holding the tissue is free of any solvent. In certain embodiments, the container holding the tissue is substantially free of solvent. In certain embodiments, the container holding the tissue is free of any flammable solvent. In certain embodiments, the container holding the tissue is substantially free of a flammable solvent, such as ethanol. For example, the container may contain frozen whole tissue, such as a whole gland, a portion of a whole gland, or a flaked tissue.

In certain embodiments, the radiation is provided at a dose sufficient to substantially inactivate resistant viruses and/or microorganisms in the tissue. In certain embodiments, the radiation is provided at a dose that prevents loss of biological, preferably enzymatic, activity relative to a control enzyme preparation isolated from unirradiated tissue.

The accelerated electron beam may be provided by an electron accelerator, such as that provided by Iotron industries USA, Inc. (Columbia City, IN). In certain embodiments, the electron accelerator operates at a power of 20 to 250 kW and a beam energy of 5 to 18 megaelectron volts (MeV). In certain embodiments, the electron accelerator operates at 60 kW and 10 MeV. In certain embodiments, the electron accelerator provides a beam energy of 10 MeV or greater.

The tissue may be exposed to the electron beam irradiation for a time and amount sufficient to effect viral or microbial inactivation without compromising the biological activity of one or more enzymes subsequently extracted or isolated from the irradiated tissue. The dose of electron beam irradiation required to sterilize tissue may vary based on the size of the tissue, the type of tissue, and the type and amount of viral or microbial contaminants in the tissue sample or suspected of being present therein. Those skilled in the art will recognize and be able to determine the appropriate dose and time appropriate for a particular tissue based on the characteristics of the tissue and accelerator to be used. The electron beam dose selected is effective for inactivating pathogens that are difficult to destroy by conventional methods, while causing minimal loss in enzyme activity.

The "absorbed dose" of radiation is expressed in kilograys (kGy), where one kilograys equals one kilojoule of energy deposited per kilogram of material. In certain embodiments, the tissue is exposed to the electron beam until an amount of radiation that inactivates the pathogen is absorbed. For example, the tissue may be exposed to the electron beam until a dose of about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, or about 50 kilograys (kGy) or more is reached. As another example, the tissue may be exposed to the electron beam until a dose of about 5 to about 50, about 10 to about 40, about 15 to about 35 kGy is achieved. In certain embodiments, the tissue is exposed to the electron beam until a dose of about 30 kGy is absorbed. In certain embodiments, the porcine pancreas is irradiated with an electron beam dose sufficient to provide a high log of pathogen, preferably a pathogen that is difficult to inactivate such as non-enveloped viruses₁₀Killing, with minimal loss in enzyme activity.

In certain embodiments, the dose may be determined using a radiochromic dye film. Such films can be calibrated by reference to national standards.

In certain embodiments, the tissue is exposed to electron beam radiation for a time and in an amount sufficient to produce at least three logs of the viral load of the model virus as compared to a control sample₁₀Preferably at least four logs₁₀And (4) reducing. In some such embodiments, the tissue is exposed to electron beam radiation for a time and amount sufficient to produce a viral load of the model virus of about three logs as compared to a control sample₁₀To about five log₁₀And (4) reducing. In some such embodiments, the tissue is exposed to electron beam radiation for a time and amount sufficient to produce a viral load of the model virus of about four logs as compared to a control sample₁₀And (4) reducing. In certain embodiments, the model virus is PPV. In certain embodiments, the tissue is an intact tissue. In some such embodiments, the intact tissue is a gland, e.g., the entire pancreatic gland or a portion thereof, e.g., one or more lobes of a pancreatic gland. In other such embodiments, the intact tissue is a frozen sheet tissue.

In certain embodiments, the electron beam exposure comprises single-sided or multi-sided exposure. In certain embodiments, the tissue is subjected to one side exposure to an electron beam. In certain embodiments, the tissue is subjected to multiple side exposure, e.g., double side exposure, to an electron beam. Thus, a dose of about 20 kGy may comprise a bilateral exposure at about 10 kGy/side; a dose of about 30 kGy may comprise a bilateral exposure at about 15 kGy/side; a dose of about 40 kGy may comprise a bilateral exposure at about 20 kGy/side; and a dose of about 50 kGy may comprise a bilateral exposure at about 25 kGy/side.

In certain embodiments, the method of preparing an enzyme preparation reduces the risk of viral or microbial infectivity of a pharmaceutical composition comprising the enzyme preparation.

In certain embodiments, the infectivity of an irradiated pancreatic gland is reduced by at least three logs relative to the infectivity of the gland prior to radiation treatment₁₀Preferably at least four logs₁₀. In certain embodiments, the infectivity of an enzyme preparation derived from or isolated from irradiated pancreatic glands is reduced by at least three logs relative to the infectivity of glands prior to irradiation treatment₁₀Preferably at least four logs₁₀. Alternatively, the infectivity of an enzyme preparation is determined relative to a control enzyme preparation derived or isolated from non-irradiated pancreatic glands.

In certain embodiments, the reduced infectivity is viral infectivity, particularly of non-enveloped viruses such as PPV. For example, pancreas isolated from irradiated pancreatic glands versus control enzyme preparations isolated from non-irradiated pancreatic glandsAt least three logs reduction in PPV infectivity of liquid products₁₀Preferably at least four logs₁₀. As another example, the PPV infectivity of irradiated pancreatic glands is reduced by at least three logs relative to non-irradiated pancreatic glands₁₀Preferably at least four logs₁₀. In some such embodiments, PPV infectivity of the enzyme preparation is further reduced by a subsequent orthogonal virus inactivation step performed after irradiation.

In certain embodiments, the method may further comprise the steps of: after the irradiating step, the tissue or an enzyme preparation derived from the tissue is tested for the presence or amount of one or more microorganisms (e.g., viruses, bacteria, or protozoa). Methods for determining whether a sample contains a microorganism are known in the art and include, for example, plaque assays or colony formation tests. Effective sterilization can also be determined using conventional microbiological techniques, for example, including a suitable biological indicator in a radiation batch, or contacting the tissue with a culture medium and then incubating the medium to determine sterility of the tissue.

In certain embodiments, the infectious dose (TCID) can be measured by end-point titration and half tissue culture₅₀) To calculate viral infectivity. The virus titer calculated in this manner can be taken as log₁₀TCID₅₀Given in/ml, with a 95% confidence interval.

In certain embodiments, the reduction in viral contamination is according to the USP-NF general section<1050>Given as the log reduction factor, the log reduction factor is the difference in viral titer between the control sample and the sample derived from the electron beam irradiated tissue after isolation. E.g. 3log₁₀A reduction may indicate a 1,000 fold reduction in viral load, while a 4 log reduction₁₀A decrease may indicate a 10,000 fold reduction in viral load.

In certain embodiments, the method of preparing an enzyme preparation allows for reduction of viral and/or microbial contamination of the enzyme preparation without substantially reducing its enzymatic activity.

In certain embodiments, the enzymatic activity of the enzyme preparation isolated from the irradiated pancreatic gland is maintained. For example, in certain embodiments, the biological activity of the enzyme preparation is at least 50%, at least 60%, at least 70%, at least 80%, or preferably at least 90% of the biological activity of a control preparation isolated from an unirradiated pancreatic gland. In certain embodiments, the biological activity is an enzymatic activity, such as a protease activity, an amylase activity, or preferably, a lipase activity.

After irradiation, the tissue may be further processed to provide an enzyme composition. For example, in certain embodiments, one or more enzymes and/or zymogens are extracted from the irradiated tissue. In certain embodiments, the one or more enzymes are isolated from the irradiated tissue. Various methods for isolating enzymes from tissue samples are known. For example, US 4,623,624 provides a method for isolating pancreatin by autolysis of a tissue slurry containing aqueous isopropanol.

In certain embodiments, the irradiated tissue may be subjected to autolysis and/or hydrolysis to convert the proenzyme into its active form. For example, irradiated tissue may be combined with a hydrolysis initiator to initiate autolysis. In certain embodiments, the autolysis and/or hydrolysis is performed at ambient temperature. In certain embodiments, the reaction mixture is filtered upon completion of the reaction; collecting the filtrate; precipitating the enzyme present in the filtrate (e.g. with isopropanol); and the precipitate was filtered, washed with isopropanol, and vacuum dried.

It will be appreciated that the methods described above and as shown in the examples section are exemplary and should not be construed as limiting the scope of the invention as defined in the appended claims. All alternatives, modifications, and equivalents of the methods and specific examples are intended to be included within the scope of the claims.

C. Composition comprising a metal oxide and a metal oxide

In at least one aspect, the invention includes a composition comprising an enzyme preparation as described herein. In certain embodiments, the composition comprises one or more enzymes and/or zymogens extracted from irradiated animal tissue. In certain embodiments, the composition comprises one or more enzymes isolated from irradiated animal tissue. In certain embodiments, the composition is a crude mixture containing one or more enzymes derived from animal tissue.

In a further aspect, there is provided a pharmaceutical composition comprising an enzyme preparation as described herein, further optionally comprising one or more conventional pharmaceutically acceptable excipients, such as those found in textbooks such as the following: remington's Pharmaceutical Sciences, 18 th edition (Alfonso R. Gennaro, eds.; MackPublishing Company, Easton, Pa., 1990); remington, The Science and Practice of pharmacy, 19 th edition ((Lippincott, Williams & Wilkins, 1995); Handbook of Pharmaceutical Excipients, 3 rd edition (Arthur H. Kibbe, eds., Amer. Pharmaceutical Assoc, 1999); The Pharmaceutical Codex: Principles and Practice of pharmaceuticals, 12 th edition (Walter Lund edition; Pharmaceutical Press, London, 1994); United States Pharmacopeia: The National Formulary (United States Pharmaceutical Convention), and Goodman and Gilman's: The Pharmaceutical basic of pharmacy (Lombiguam, Inc. of Pharmaceutical, 1992), incorporated by reference herein.

The pharmaceutical composition comprising an enzyme preparation as described herein may be used for supplementation of digestive enzymes in the treatment and/or prevention of dyspepsia in mammals, in particular dyspepsia due to chronic pancreatic exocrine insufficiency (e.g. in patients with cystic fibrosis, chronic pancreatitis or patients who have undergone surgery of the upper digestive tract). The pharmaceutical composition or dosage form as described herein may preferably be an oral dosage form, which may be specifically administered to a human.

The oral dosage form containing the enzyme preparation may be in the form of, for example, capsules, granules, pellets, microspheres, microtablets, pellets, pills, powders and/or tablets. For the purposes of this specification, the prefix "micro" is used to describe an oral dosage form if its diameter or all its dimensions (length, height, width) are equal to or less than about 5 mm.

In certain embodiments, the oral dosage form is a capsule. The capsule may comprise from about 2,000 to about 40,000 lipase units per capsule. In certain embodiments, the oral dosage form is a capsule comprising 3,000, 6,000, 12,000, 24,000, or 36,000 lipase units per capsule. In certain implementations, the oral dosage form is a capsule comprising 3,000, 5,000, 10,000, 15,000, 20,000, 25,000, or 40,000 lipase units per capsule. In certain embodiments, the oral dosage form is a capsule comprising 2,600, 4,200, 10,500, 16,800, or 21,000 lipase units per capsule. In certain embodiments, the oral dosage form is a capsule comprising 4,000, 13,800, 20,700, or 23,000 lipase units per capsule. In certain embodiments, the oral dosage form is a capsule comprising 4,000, 8,000, or 16,000 lipase units per capsule. In certain embodiments, the oral dosage form is a capsule comprising 4,000, 8,000, or 16,000 lipase units per capsule. In other embodiments, the oral dosage form is a capsule comprising 3,000, 4,000, 6,000, or 8,000 lipase units per capsule. Dosage strength can be expressed by various means, including in USP units, european pharmacopoeia units, or BP units.

In certain embodiments, the oral dosage form is a tablet comprising 10,440 or 20,880 lipase units per tablet.

Various pharmaceutical compositions and dosage forms containing pancreatin are known, such as delayed release and immediate release compositions. For example, US 9,198,871 provides a delayed release pancreatin composition.

In certain embodiments, the oral dosage form is pancreatin micropellets or pancreatin microspheres. In certain embodiments, the pancreatin micropellets or pancreatin microspheres are coated, for example, with an enteric coating. In certain embodiments, the pancreatin micropellets or pancreatin microspheres (independent of any such coating) comprise from about 10% to about 95% by weight pancreatin, from about 5% to about 90% by weight at least one pharmaceutically acceptable binding agent, and from 0% to about 10% by weight at least one pharmaceutically acceptable excipient. More specifically, pancreatin micropellets or pancreatin microspheres comprise from about 70% to about 90% by weight pancreatin, from about 10% to about 30% by weight at least one pharmaceutically acceptable binder, and from about 0% to about 5% by weight at least one pharmaceutically acceptable excipient. In certain embodiments, the pancreatin micropellets or pancreatin microspheres comprise from about 70% to about 90% by weight pancreatin, and from about 10% to about 30% by weight of at least one pharmaceutically acceptable binding agent. In certain embodiments, the pancreatin micropellets or pancreatin microspheres are approximately spherical and have a diameter of about 0.5 mm to about 2.0 mm. In certain embodiments, the pancreatin micropellets or pancreatin microspheres have a first size of about 0.5 mm to about 2.0 mm, and a second size of about 0.5 mm to about 2.0 mm. In certain embodiments, the pancreatin micropellets or pancreatin microspheres have a first dimension of about 0.8 mm to about 1.0 mm, and a second dimension of about 0.5 mm to about 2.0 mm.

Examples of pharmaceutically acceptable binders include polyethylene glycol 1500, polyethylene glycol 2000, polyethylene glycol 3000, polyethylene glycol 4000, polyethylene glycol 6000, polyethylene glycol 8000, polyethylene glycol 10000, hydroxypropyl methylcellulose, polyoxyethylene, copolymers of polyoxyethylene-polyoxypropylene and mixtures of said organic polymers. The foregoing list of pharmaceutically acceptable binding agents is not meant to be exhaustive, but is merely illustrative, as one of ordinary skill in the art will appreciate that many other pharmaceutically acceptable binding agents or combinations of binding agents may also be used. Polyethylene glycol 4000 is a preferred pharmaceutically acceptable binder.

Examples of suitable pharmaceutically acceptable excipients include glidants such as magnesium or calcium stearate, stearic acid, talc and/or starch; fillers such as calcium phosphate, corn starch, dextran, dextrin, hydrated silicon dioxide, microcrystalline cellulose, kaolin, lactose, mannitol, polyvinylpyrrolidone, precipitated calcium carbonate, sorbitol and/or talc; disintegrants such as Aerosil (silicic acid), alginic acid, amylose, calcium alginate, calcium carbonate, formaldehyde gelatin, pectin carbonate, sago starch, sodium bicarbonate and/or starch; and/or humectants such as glycerin and/or starch. The foregoing list of pharmaceutically acceptable excipients is not meant to be exhaustive, but merely illustrative, as one of ordinary skill in the art will appreciate that many other pharmaceutically acceptable excipients or combinations of excipients may also be used. For the purposes of this disclosure, synthetic oils and monomeric phthalates are not considered suitable pharmaceutically acceptable excipients. In certain embodiments, the pancreatin micropellets or pancreatin microspheres are free of pharmaceutically acceptable excipients, but may optionally contain larger amounts of pancreatin.

In another embodiment, an oral dosage form of pancreatin, e.g., an enterically coated oral dosage form, is provided for use in the manufacture of a medicament for treating a medical condition, e.g., digestive disorders, pancreatic exocrine insufficiency, pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II.

In certain embodiments, the pharmaceutical composition is a controlled release pharmaceutical composition. For example, controlled release pharmaceutical compositions may be obtained by applying an enteric coating to an oral dosage form. In certain embodiments, the enteric coating comprises a film-forming agent, a plasticizer, and optionally an anti-adherent.

Suitable film formers include agar, carbomer homopolymers and copolymers (i.e., high molecular weight, crosslinked acrylic-based polymers), carboxymethyl cellulose, carboxymethylethyl cellulose, carrageenan, cellulose acetate phthalate, cellulose acetate succinate, cellulose acetate trimellitate, chitin, zein extract, ethyl cellulose, gum arabic, hydroxypropyl cellulose, hydroxypropyl methyl succinate acetate, hydroxypropyl methyl cellulose acetate succinate, hydroxypropyl methyl cellulose phthalate, methacrylic acid-ethyl methacrylate copolymers, methylcellulose, pectin, polyvinyl acetate phthalate, polyvinyl alcohol, shellac, sodium alginate, starch acetate phthalate and/or styrene/maleic acid copolymers or mixtures of said film-forming polymers. Cellulose acetate phthalate, hydroxypropyl methylcellulose acetate succinate and/or methacrylic acid-ethyl methacrylate copolymers are preferred film formers. Most preferred is hydroxypropylmethylcellulose phthalate, such as HP 55 or HPMCP HP-50. Synthetic oils are not considered to be a preferred film former. The foregoing list of film formers is not meant to be exhaustive, but merely illustrative, as one of ordinary skill in the art will appreciate that many other film formers or combinations of film formers may also be used.

Plasticizers can generally be present in amounts greater than about 1.5% by weight, and typically in amounts of about 2% to about 20% relative to the film former. The plasticizer may contain a saturated linear monohydric alcohol having 12 to 30 carbon atoms. More specifically, acceptable plasticizers include lauryl alcohol, tridecyl alcohol, myristyl alcohol, pentadecyl alcohol, cetyl alcohol, heptadecyl alcohol, stearyl alcohol, nonadecyl alcohol, arachidyl alcohol, behenyl alcohol, carnauba alcohol, ceryl alcohol, linalool, melittic alcohol, acetyl tributyl citrate, dibutyl sebacate, fatty acid esters of glycerol, polyethylene glycol, propylene glycol, sorbitan fatty acids, triacetin, triethyl citrate, and mixtures of the plasticizers. Preferred plasticizers are cetyl alcohol, stearyl alcohol, triethyl citrate and mixtures thereof. When cetyl alcohol is used as the sole plasticizer, it may be present in an amount greater than about 1.5% by weight, typically in an amount of from about 2% to about 15%, preferably from about 2% to about 10%, relative to the film former. When triethyl citrate is used as the sole plasticizer, it may be present in an amount of about 5% to about 20%, preferably about 12% to about 15% by weight relative to the film forming agent. Synthetic oils and monomeric phthalates are not considered suitable plasticizers. The foregoing list of plasticizers is not meant to be exhaustive, but merely illustrative, as one of ordinary skill in the art will appreciate that many other plasticizers or combinations of plasticizers may also be used, so long as they are substantially free of both synthetic oils and monomeric phthalates.

In certain embodiments, the plasticizer comprises cetyl alcohol and triethyl citrate, collectively in an amount greater than about 3% by weight, typically in an amount of about 4% to about 20%, specifically about 6% to about 15%, relative to the film former. More particularly about 7% to about 10%. When both are present, the weight ratio of cetyl alcohol to triethyl citrate may be about 0.05: 1 to about 1: 1, e.g. 0.1: 1. 0.2: 1. 0.3: 1. 0.4: 1. 0.5: 1. 0.6: 1. 0.7: 1. 0.8: 1 or 0.9: 1. in particular, the ratio of cetyl alcohol to triethyl citrate may be about 0.25: 1 to about 0.5: 1, preferably about 0.3: 1 to about 0.45: 1, more preferably about 0.35: 1 to about 0.4: 1, and even more preferably about 0.38: 1 to about 0.4: 1 (w/w).

The enteric coating optionally comprises an anti-adherent. Suitable anti-tacking agents include dimethicone and castor oil. Dimethicone, particularly dimethicone 1000, is a preferred anti-tack agent. The amount of anti-tacking agent (if present) in the enteric coating is about 1.5% to about 3% by weight relative to the film forming agent. Synthetic oils are not considered as preferred anti-tack agents. The foregoing list of anti-tacking agents is not meant to be exhaustive, but is merely illustrative, as one of ordinary skill in the art will appreciate that many other anti-tacking agents or combinations of anti-tacking agents may also be used.

In certain embodiments, the enteric coating comprises from about 5% to about 30% by weight, more preferably from about 7% to about 20% by weight, and even more preferably from about 10% to about 15% by weight of the total composition or controlled release pharmaceutical composition of the enteric oral dosage form. In certain embodiments, the enteric coating comprises from about 20% to about 30% by weight, more preferably from about 22% to about 26% by weight, and even more preferably from about 22.5% to about 25% by weight of the total composition or controlled release pharmaceutical composition of the enteric oral dosage form.

In certain embodiments, the pharmaceutical composition is a controlled release capsule for oral administration. The capsules may contain enteric pellets comprising lipase, protease and amylase. The enteric pellets can have a first size of about 0.5 mm to about 2.0 mm, and optionally a second size of about 0.5 mm to about 2.0 mm. For example, enteric pellets can be approximately spherical and have a diameter of about 0.71 to about 1.60 mm. As another example, enteric pellets may be strand-shaped and have a diameter of about 0.5 mm to about 2.0 mm, and a length of about 0.5 mm to about 2.0 mm. The composition may further comprise inactive ingredients as described herein, such as cetyl alcohol, dimethicone, hydroxypropyl methylcellulose phthalate, polyethylene glycol, and triethyl citrate.

In certain other embodiments, the pharmaceutical composition is an immediate release pharmaceutical composition. For example, an immediate release pharmaceutical composition may lack an enteric coating.

D. Application method

In at least one aspect, the invention includes methods of treating exocrine pancreatic insufficiency in a subject, particularly a human subject, in need of such treatment. The method comprises administering to the subject an enzyme preparation or a pharmaceutical composition comprising an enzyme preparation. In certain embodiments, pancreatic exocrine insufficiency is due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.

In another aspect, the invention includes a method of treating or preventing dyspepsia in a subject, particularly a human subject, in need of such treatment or prevention. In certain embodiments, the dyspepsia is due to chronic exocrine pancreatic insufficiency, for example, in a subject with cystic fibrosis, chronic pancreatitis, or a patient who has undergone surgery on the upper digestive tract.

In another aspect, the invention includes the use of an enzyme preparation or a pharmaceutical composition containing an enzyme preparation for the treatment of exocrine pancreatic insufficiency in a subject in need of such treatment.

In another aspect, the invention includes the use of an enzyme preparation or a pharmaceutical composition containing an enzyme preparation for the treatment or prevention of dyspepsia in a subject in need of such treatment or prevention.

In certain embodiments related to the above methods and uses, the enzyme preparation comprises pancreatin. In certain embodiments, a suitable dosage of pancreatin may be based on lipase units. The Cystic Fibrosis Foundation (CFF) has published consensus guidelines containing a recommended total daily dose of lipase units.

In certain embodiments, 2,000 to 4,000 lipase units, preferably 3,000 lipase units per 120 mL formula or breast feeding is administered to infants up to 12 months.

In certain embodiments, 1,000 to 2,500 lipase units/kg body weight/meal are administered to an individual between one (1) and four (4) years of age. In certain embodiments, 500 to 2500 lipase units/kg body weight/meal are administered to an individual who is at least four (4) years of age.

In certain embodiments, the maximum daily dose does not exceed 10,000 lipase units/kg body weight. In certain embodiments, the maximum daily dose does not exceed 4,000 lipase units per gram of fat ingested.

In certain embodiments, the enzyme preparation or the pharmaceutical composition containing the enzyme preparation is administered immediately before meals. In certain embodiments, the enzyme preparation or the pharmaceutical composition containing the enzyme preparation is administered during a meal or snack.

In yet another embodiment, a method for treating a medical condition such as digestive disorders, pancreatic exocrine insufficiency, pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II by administering a therapeutically effective amount of an enzyme preparation, or a pharmaceutical composition comprising an enzyme preparation, to an individual in need of such treatment is provided.

In at least one aspect, the invention includes a method of digesting a protein. The method comprises contacting the protein to be digested with an enzyme preparation under conditions sufficient to digest the protein.

In certain embodiments, the enzyme preparation comprises one or more enzymes and/or zymogens extracted from electron beam irradiated animal tissue. In certain embodiments, the enzyme preparation comprises one or more enzymes isolated from electron beam irradiated animal tissue. In certain embodiments, the enzyme preparation is in crude form.

In certain embodiments, the contacting step occurs in vivo. In certain embodiments, the contacting step occurs in vitro.

In certain embodiments, the digested protein is used to prepare a protein hydrolysate.

The enzyme preparations, compositions, methods and uses described herein will be better understood by reference to the following exemplary embodiments and examples, which are included as illustrations of the scope of the invention and not as limitations.

E. Exemplary embodiments

One aspect of the invention includes an enzyme preparation produced by a method comprising the steps of: (a) providing mammalian pancreatic tissue; (b) Subjecting pancreatic tissue to electron beam radiation to produce irradiated pancreatic tissue, wherein the electron beam radiation is sufficient to produce a reduction in microbial and/or viral load; and (c) isolating pancreatin from the irradiated pancreatic tissue. In certain embodiments, the isolating step comprises initiating hydrolysis or autolysis of pancreatic tissue. In certain embodiments, the separating step comprises mixing the irradiated pancreatic tissue with water. In certain embodiments, step (c) comprises activating a zymogen from the irradiated pancreatic tissue. In certain embodiments, the reduction in microbial and/or viral load is at least three logs relative to a control sample obtained from unirradiated tissue₁₀Preferably at least four logs₁₀And (4) reducing. For example, the reduction in microbial and/or viral load is at least three logs of PPV viral load relative to a control sample obtained from unirradiated tissue₁₀Preferably at least four logs₁₀And (4) reducing. In certain embodiments, the biological activity of the enzyme preparation obtained in step (c) corresponds to at least 50%, preferably at least 90%, of the biological activity of a control enzyme preparation obtained from non-irradiated pancreatic tissue. In certain embodiments, the biological activity is lipase activity. In certain embodiments, the biological activity is protease activity or amylase activity. In certain embodiments, the method further comprises one or more additional steps that provide for additional reduction in microbial and/or viral load.

Another aspect of the invention includes an enzyme preparation comprising one or more enzymes isolated from mammalian tissue subjected to at least three logs sufficient to generate a viral load₁₀Preferably at least four logs₁₀Reduced processing. For example, the treatment is sufficient to produce at least three logs of PPV viral load relative to an unirradiated control sample₁₀Preferably at least four logs₁₀And (4) reducing.

Another aspect of the invention includes an enzyme preparation comprising one or more enzymes isolated from mammalian tissue, wherein prior to enzyme isolation, the mammalian tissue has been subjected to at least three logs sufficient to generate a viral load₁₀Preferably at least four logs₁₀Reduced processing. For example, the treatment is sufficient to produce at least three logs of PPV viral load relative to an untreated control sample₁₀Preferably at least four logs₁₀And (4) reducing. In certain embodiments, the mammalian tissue is porcine pancreas. In certain embodiments, the porcine pancreas is flaked. In certain embodiments, the porcine pancreas is in a frozen mass. In certain embodiments, the porcine pancreas is the entire gland or a portion thereof, such as one or more leaves. In certain embodiments, the one or more enzymes comprise pancreatin. In certain embodiments, the treatment comprises electron beam radiation. In certain embodiments, the electron beam radiation has a dose of about 5 to about 50 kGy, preferably about 10 to about 40 kGy. In certain embodiments, the biological activity of the enzyme preparation corresponds to at least 50%, preferably at least 90%, of the biological activity of a control enzyme preparation obtained from untreated mammalian tissue. In certain embodiments, the biological activity is lipase activity. In certain embodiments, the biological activity is protease activity or amylase activity. In certain embodiments, the reduction in viral load is an orthogonal reduction.

Another aspect of the invention includes a method for reducing the risk of contamination of pancreatic juice product with pathogens comprising the steps of: (a) providing mammalian pancreatic tissue; (b) subjecting pancreatic tissue to electron beam radiation to produce irradiated pancreatic tissue, wherein the electron beam radiation is sufficient to reduce the risk of contamination by pathogens; and (c) isolating pancreatin from the irradiated pancreatic tissue, thereby obtaining a pancreatin product having a reduced risk of contamination with pathogens relative to the mammalian pancreatic tissue provided in step (a) or a pancreatin sample derived from non-irradiated pancreatic tissue. In certain embodiments, the pathogen is Porcine Parvovirus (PPV). In certain embodiments, the methods provide at least three logs of a measure indicative of the level or activity of a non-enveloped virus, such as Porcine Parvovirus (PPV)₁₀Preferably at least four logs₁₀And (4) reducing. In certain embodiments, the measure indicative of the level or activity of non-enveloped viruses is viral load.

Another aspect of the invention includes an enzyme preparation comprising one or more enzymes isolated from mammalian tissue and a substantially inactivated non-enveloped virus, wherein the preparation has a biological activity corresponding to at least 50%, preferably at least 90% of the biological activity of a control preparation. In certain embodiments, the control formulation is not subjected to a treatment sufficient to inactivate non-enveloped viruses. In certain embodiments, the substantially inactivated non-enveloped virus is Porcine Parvovirus (PPV). In certain embodiments, the one or more enzymes comprise pancreatin. In certain embodiments, one or more enzymes are isolated from mammalian tissue. In certain embodiments, the mammalian tissue is electron beam irradiated mammalian tissue.

Another aspect of the invention comprises a pharmaceutical composition comprising one or more enzymes isolated from mammalian tissue that has been subjected to a treatment that reduces the risk of viral and microbial infection, wherein the composition has a biological activity that corresponds to at least 50%, preferably at least 90%, of the biological activity of a control composition. In certain embodiments, the one or more enzymes comprise a lipase. In certain embodiments, the control composition comprises an untreated mammalian tissue sample corresponding to mammalian tissue that has been treated to reduce the risk of viral and microbial infection. In certain embodiments, the treatment comprises electron beam radiation. In certain embodiments, the electron beam radiation has a dose of about 5 to about 50 kGy, preferably about 10 to about 40 kGy.

Another aspect of the invention includes a method for producing a pancreatin product, comprising the steps of: (a) providing mammalian pancreatic tissue; (b) subjecting pancreatic tissue to electron beam radiation to produce irradiated pancreatic tissue; and (c) separating pancreatin from the irradiated pancreatic tissue to obtain a pancreatin product. In certain embodiments, the biological activity of the pancreatin product obtained in step (c) corresponds to at least 50%, preferably at least 90%, of the biological activity of a control pancreatin product. In certain embodiments, the control pancreatin product is obtained from non-irradiated pancreatic tissue. In certain embodiments, electron beam radiation is sufficient to generate viral vectorsAt least three logs of quantity₁₀Preferably at least four logs₁₀And (4) reducing. For example, the reduction in viral load that the treatment is sufficient to produce relative to an unirradiated control sample is at least three logs of the viral load of PPV₁₀Preferably at least four logs₁₀And (4) reducing. In certain embodiments, the electron beam radiation has a dose of about 5 to about 50 kGy, preferably about 10 to about 40 kGy. In certain embodiments, the biological activity is lipase activity. In certain embodiments, the biological activity is protease activity or amylase activity.

Another aspect of the invention includes a method for digesting protein comprising the steps of: (a) providing an enzyme or zymogen preparation isolated from electron beam irradiated animal tissue; and (b) contacting the protein with an enzyme or enzyme preparation under conditions sufficient to digest the protein. In certain embodiments, the contacting step occurs in vivo. In certain embodiments, the contacting step occurs in vitro. In certain embodiments, the animal tissue is porcine pancreas. In certain embodiments, the digested protein is used to prepare a protein hydrolysate. In certain embodiments, the enzyme or zymogen preparation derived from electron beam irradiated animal tissue exhibits at least three logs of viral load as compared to a control enzyme or zymogen preparation derived from non-irradiated animal tissue₁₀Preferably at least four logs₁₀And (4) reducing. In certain embodiments, the enzyme or zymogen preparation derived from electron beam irradiated animal tissue exhibits a biological activity corresponding to at least 50%, preferably at least 90%, of the biological activity of a control enzyme or zymogen preparation derived from non-irradiated animal tissue.

Another aspect of the invention includes an enzyme preparation comprising one or more enzymes isolated from electron beam irradiated pancreatic tissue. In certain embodiments, the pancreatic tissue comprises porcine pancreas. In certain embodiments, the porcine pancreas is frozen and machined into slices or chunks prior to irradiation. Thus, in some such embodiments, the pancreatic tissue subjected to electron beam irradiation is a sheet of frozen pancreatic tissue or a frozen mass of pancreatic tissue. In certain embodiments, the porcine pancreas is the entire gland or a portion thereof,such as one or more leaves. In certain embodiments, the one or more enzymes comprise pancreatin. In certain embodiments, the enzyme preparation exhibits at least three logs of viral load as compared to a control enzyme preparation₁₀Preferably at least four logs₁₀And (4) reducing. For example, the enzyme preparation exhibits at least three logs of PPV viral load relative to a control enzyme preparation₁₀Preferably at least four logs₁₀And (4) reducing. In certain embodiments, the biological activity of the enzyme preparation corresponds to at least 50%, preferably at least 90% of the biological activity of the control enzyme preparation. In certain embodiments, the biological activity is lipase activity. In certain embodiments, the biological activity is protease activity or amylase activity. In certain embodiments, the control enzyme preparation is obtained from non-irradiated tissue. In certain embodiments, the reduction in viral load is an orthogonal reduction.

Another aspect of the invention includes a method of treating exocrine pancreatic insufficiency, comprising: administering to a subject in need thereof a dose of any of the foregoing enzyme preparations and/or pharmaceutical compositions. In certain embodiments, pancreatic exocrine insufficiency is due to cystic fibrosis or chronic pancreatitis.

F. Examples of the embodiments

Example 1 Electron Beam irradiation of Porcine ParvoVirus (PPV), pancreatin API and porcine pancreas

Materials and methods.

Vial-filled porcine parvovirus in cell culture fluid. Since porcine glandular tissue itself may have some inactivation effect on the virus, initially, virus samples for these studies were prepared from infected cell cultures. Porcine Parvovirus (PPV), Strain NADL-2 (ATCC)^®VR-742) and porcine testis (ST) cells (ATCC)^®CRL-1746) was purchased from the American Type Culture Collection (ATCC). PPV was propagated, cultured and maintained according to ATCC recommendations. PPV reproduction to about 10⁸Titer of viral Infection Units (IU)/ml. The virus is harvested from lysed cells in a cell culture medium consisting of Minimal Essential Medium (MEM), 10% Fetal Bovine Serum (FBS),2 mM glutamine, 100 units/ml penicillin, 100 mg/ml streptomycin.

PPV is packaged in vials and then double bagged prior to shipping. The vials were Nalgene cryogenicvideos (i.e., High Density Polyethylene (HDPE) closed polypropylene with external threads, with a leak-proof sealing ring, 1.87 in length, 0.5 in diameter, 2.0 ml capacity, and 1.0 ml fill volume. each individual vial was placed into a Food Saver bag (polyethylene with a nylon outer layer) and vacuum sealed.

Frozen sheet porcine pancreatic gland. Pancreatic glands obtained from slaughtered pork pigs (Animal Technologies, Tyler, TX) were kept on dry ice.

Frozen, flaked porcine pancreatic glands were placed in a 12 "x 12" x1 "container of microspheres (clear polypropylene) vacuum sealed in a 3 mil poly/nylon bag. The bag is heat sealed. The pancreatic glands were kept on dry ice to ensure a temperature below-20 ℃. The sample weight of frozen flaked porcine pancreatic glands was 1.05 kg plus a package weight of 270 grams (0.27 kg). The lid weighed 100 g. The surface density was 1.3 g/cm². For each radiation dose, including the no-radiation control, two packages were prepared, one complete package for enzyme preparation separation after shipping back to the site where separation was performed, and the other package was kept in stock.

Pancreatic juice extract (API). Two types of pancreatin APIs were used: pancreatin N and pancreatin S. Both APIs were kept at ambient conditions. Pancreatin N (material # 1030828, Abbott Laboratories) is a pale yellow/gray to off-white powder. Pancreatin N is derived from slaughtered pork pig pancreas. Pancreatin S (material #1030829, Abbott Laboratories) is a pale yellow/gray to off-white powder. Pancreatic juice S is derived from the pancreas of sows.

A pancreatic hormone API is placed in a2 ZA "x 3" x1 ⅝ "container (clear polypropylene) vacuum sealed within a 3 mil poly/nylon bag. The bag is heat sealed. Pancreas (pancreas)The sample weight of the liquiritin API was 80 grams plus a package weight of 26 grams. The surface density was 1.4 g/cm². A sample of pancreatin N was exposed to an indicated dose of electron beam radiation. The control was not exposed to electron beam radiation. The activity of pancreatin N was determined after transport back to the experimental site. Pancreatin N is derived from slaughtered pork pigs. All pancreatin N packages arrive intact from the irradiation site.

And (4) irradiating an electron beam.

The source of the Electron beam was Industrial Materials Processing Electron Linear Electron Carrier (IMPELA;. Iotron Industries, Inc. Columbia City, IN), 10 MeV, 80 cm scan width.

The packed frozen pellet samples of porcine pancreas and porcine parvovirus were kept below-20 ℃ by placing on dry ice contained in an aluminum pan. The dosimeter was placed on the upper surface of each sample. A packed pancreatin API sample maintained at room temperature was placed on expanded polystyrene foam sheet and the dosimeter was placed on the top surface. The packages are sent onto a conveyor belt under the scan angle of the electron beam. After one pass of the radiation, the dosimeter is retrieved. After inverting the package (now upside down), the package is sent under the radiation angle for a second pass and a new dosimeter is placed on the upper surface. After the second round of irradiation, the package and dosimeter were removed. Frozen flaked porcine pancreas and porcine parvovirus packages were retrieved and placed on dry ice for shipment. The packaging of the pancreatin API is retrieved and kept at ambient temperature for shipping. Control packages of frozen pancreata flaked and porcine parvovirus placed on dry ice were prepared for re-shipment on dry ice without undergoing radiation. A control package of pancreatin API maintained at ambient temperature was prepared for shipping again at ambient temperature without undergoing radiation. Using the calibration curve, the electron beam dose was calculated from the dosimeter exposure.

And (4) testing virus infectivity.

Viral infectivity was determined by titration of 10-fold dilutions in 96-well microplates using appropriate controls for triplicate samples at each energy dose. Reed, l.j. was used; muench, H. (1938).Virus titers were calculated by The Reed and Muench methods described in "A simple method evaluating Fifty percent ends", "The American Journal of Hyperene 27: 493-497, and expressed as 50% TCID₅₀/mL。

Pancreatin isolation and testing.

The process for separating pancreatin is substantially similar to the process described in US 4,623,624, which comprises hydrolysis and/or autolysis followed by fiber sieving, enzyme precipitation, separation of the precipitate by filtration and/or centrifugation, washing of the filter cake, drying and particle size reduction. Hydrolysis was performed using one package corresponding to each radiation dose including the unirradiated control. Packages without package damage (e.g. large cracks) were selected for each separation experiment. Due to the care taken in shipping back to the laboratory site, all packages were reached in their entirety and one package was randomly selected for each radiation dose including controls for separation. Pancreatin from an earlier separation was used as a source of protease to start the hydrolysis. Calcium hydroxide is used to supply the calcium ions required for protease activation. Sodium bicarbonate was used as a buffer for hydrolysis. Dimethicone was used as the defoamer. Hydrolysis of the pancreas is performed close to ambient temperature. Completion of hydrolysis was checked by centrifuging the hydrolysis mixture after isopropanol addition as described below. After the hydrolysis was complete, additional isopropanol was added to reduce the hydrolysis rate, the mixture was cooled, the mixture was stirred, and the fibers were separated using a 0.425 inch screen. The fibers were washed with isopropanol and compressed to drain the retained liquid. The wash was combined with the filtrate obtained earlier. Additional isopropanol was added to the filtrate to cause precipitation of the enzyme. The suspension was filtered through a filter cloth with 15 micron openings and washed with increasing concentrations of isopropanol with anhydrous isopropanol as the final wash. The filter cake was dried on the filter cloth under a nitrogen flow while a vacuum was pulled under the filter cloth until the filter cake visually appeared dry (the color of the filter cake became lighter after the isopropanol and water were removed). The filter cake is stripped from the filter cloth and dried under vacuum and a flow of nitrogen at a temperature below about 50 ℃ to a water content of 3.5% or less by Karl Fischer. The yield of dry pancreatin is 80 to 100g from 1 Kg of frozen flaked pig pancreas from slaughtered pork pigs.

Centrifugation test for completion of hydrolysis. Three spoons of about 10 ml were sampled from the hydrolysis vessel and the filtrate was collected into a plastic beaker (the filtrate was also scraped into the plastic beaker) through a 0.425 mm sieve, discarding the fiber remaining on the screen. Using a pipette, add 10 g of the solution from the reactor to a 50 mL centrifuge tube, add 5.5mL IPA 85%, stir with a spatula for 1 minute. 20 mL IPA 85% was added to the filtrate in a 50% centrifuge tube. Stir with spatula for one minute. The suspension was centrifuged for two minutes at about 90X g.

The first sample can be taken two hours after the hydrolysis begins or when the color changes from pink to brown and the suspension becomes thin (about 2 hours).

When the color is brown without pink shades, the next sample is taken, at which time the sediment is expected to be about 25%, the sediment is not too hard, and the stray (straggler) can be present in the upper clear layer. Thereafter, sampling is completed every half hour when possible.

Hydrolysis was stopped if two subsequent measurements showed less than 20% sediment. At this point, the sediment will be hard and free of stray matter in the upper transparent layer.

Double-sided electron beam irradiation of PPV packed in vials was performed in triplicate. The viral load reduction and log kill data for PPV exposed to e-beam radiation are shown in table 1:

dosage (KGy)

0

9.5

19.25

38.45

0

9.5

19.25

38.45

Viral load

Viral load

Viral load

Viral load

Logarithmic kill

Logarithmic kill

Logarithmic kill

Logarithmic kill

Viral titer/mL

Viral titer/mL

Viral titer/mL

Viral titer/mL

Test A

1.50E+08

2.50E+06

1.50E+05

0.00E+00

1.78E+00

3.00E+00

Test B

1.50E+08

6.34E+06

6.34E+04

0

1.37E+00

3.37E+00

Test C

4.00E+08

1.26E+06

4.00E+05

1.50E+02

0

2.50E+00

3.00E+00

6.43E+00

Mean value of

0

1.88E+00

3.12E+00

6.43E+00

The electron beam dose was determined by estimating the dose absorbed by each sample from the surface dose as indicated by the dosimeter attached to the sample container.

Table 1 shows that exposure of PPV to about 40 kGy provides about 6.5 log₁₀Killing, while exposure to about 20 kGy provided about 3 logs₁₀And (5) killing. Based on these data, exposure to about 30 kGy is expected to provide at least 4 logs₁₀And (5) killing.

Exposure of PPV to about 60 kGy, about 80 kGy, or about 100 kGy results in a final viral titer below the detection limit of the assay.

Pancreatin was tested for free protease, amylase and lipase activities by validated methods as described in USP. The total protein enzymes of pancreatin were tested by a validated method as described in the European Pharmacopoeia (EP).

Two-sided electron beam irradiation of pancreatin N was performed. All pancreatin N containers were retrieved intact at the laboratory site and used for the assay. The enzymatic activity data for pancreatin API exposed to electron beam radiation are shown in table 2:

electron beam dose	Lipase enzymeActivity of	Amylase Activity	Total protease Activity	Free protease Activity
					KGy	USP unit/g	USP unit/g	USP unit/g	USP unit/g
Control (0 kGy)	89106	564390	383192	314093
					18.6 kGy	63328	398752	321567	266540
37.45 kGy	58631	386628	302341	244531
					56.5 kGy	47755	282378	272499	232087
76.35 kGy	40583	272760	259117	214914
					99.4 kGy	37799	286652	247005	196356

Table 2 shows that exposure of pancreatin API to about 20 kGy provides about 30% loss in lipase activity, exposure of pancreatin API to about 40 kGy provides about 35% loss in lipase activity, exposure of pancreatin API to about 60 kGy provides about 46% loss in lipase activity, exposure of pancreatin API to about 80 kGy provides about 54% loss in lipase activity, and exposure of pancreatin API to about 100 kGy provides about 58% loss in lipase activity. Based on these data, exposure of pancreatin API to about 30 kGy is expected to provide at least a 30% loss in lipase activity.

Two-sided electron beam irradiation of slaughtered pork pig pancreata was performed. The enzymatic activity data for pancreatin derived from frozen flaked porcine pancreatic glands exposed to electron beam radiation are shown in table 3:

electron beam dose	Lipase Activity	Amylase Activity	Total proteaseActivity of	Free protease Activity
					KGy	USP unit/g	USP unit/g	USP unit/g	USP unit/g
Control (0 kGy)	74986	423487	243421	151365
					18.75 kGy	74741	449569	337594	128749
35.5 kGy	65348	349816	360407	128506
					56.55 kGy	57976	398281	268297	119727
77.4 kGy	34806	251691	175994	109158
					100.4 kGy	36362	276118	206217	100342

Table 3 shows that exposure of frozen flaked porcine pancreas to about 20 kGy provides about a 1% loss in lipase activity, exposure of frozen flaked porcine pancreas to about 40 kGy provides about a 13% loss in lipase activity, exposure of frozen flaked porcine pancreas to about 60 kGy provides about a 23% loss in lipase activity, exposure of frozen flaked porcine pancreas to about 80 kGy provides about a 54% loss in lipase activity, and exposure of frozen flaked porcine pancreas to about 100 kGy provides about a 52% loss in lipase activity. Based on these data, exposure of frozen flaked porcine pancreatic glands to about 30 kGy is expected to provide about a 10% loss in lipase activity.

As shown in tables 2 and 3, electron beam irradiation of pancreatin API produced more loss of enzyme activity compared to electron beam irradiation of pancreatic tissue prior to isolation. Without wishing to be bound by theory, the resistance of intact tissue to electron beam irradiation may be due to the conformation of enzymes (e.g., as zymogens) in the source tissue and/or cofactors providing structural protection in the source tissue.